MedTrace Logo

CArdioMetabolism and Atherosclerotic PlaqUe progreSsion

NCT05117424 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2024-08-06

No results posted yet for this study

Summary

Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.

Conditions

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Lin Lu, M.D., Ph.D. · Ruijin Hospital, Shanghai Jiaotong School of Medicine

  • Fenghua Ding, M.D., Ph.D. · Ruijin Hospital, Shanghai Jiaotong School of Medicine

  • Ruiyan Zhang, M.D., Ph.D. · Ruijin Hospital, Shanghai Jiaotong School of Medicine

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05117424 on ClinicalTrials.gov